



AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Corp Office: H.No 1769, Phase 3B2, Mohali-160059

Phone: 0172-5020758-69 Website: www.ajoonibiotech.com

E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com

CIN: L85190PB2010PLC040162

August 14, 2025

To,
National Stock Exchange of India Ltd
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400051

Dear Sir / Madam,

SYMBOL: AJOONI

Sub.: Approval of Un-Audited Financial Results for the quarter ended 30th June 2025.

Dear Sir,

Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform that the Board of Directors of the Company at their meeting held on Thursday, August 14, 2025 at the Corporate Office of the company have considered and approved the un-Audited Financial Statements for the quarter ended on 30th June 2025. In this regards, we are enclosing herewith:


1. Un-Audited Financial Results for the quarter ended on 30th June 2025 as recommended by the Audit Committee.
2. Limited Review Report from the auditor for the quarter ended June 30, 2024.

You are requested to kindly take the same on record.


Thanking You,
Yours Truly,
For Ajooni Biotech Limited

Swati Vijan
Company Secretary
FCS13627

AJOONI BIOTECH LIMITED							
CIN : L85190PB2010PLC040162							
STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2025(In Lakhs)							
	PARTICULARS	QUARTER ENDED					Year Ended (Audited)
		30.06.2025	31.03.2025	30.06.2024	Period Ended (UnAudited) 30.06.2025	Period Ended (UnAudited) 30.06.2024	31.03.2025
I	Income						
	Revenue from operations	3,126.77	2,927.44	2,565.85	3,126.77	2,565.85	11,469.19
	Other income	64.54	133.64	3.67	64.54	3.67	206.90
	Total income from operations	3,191.31	3,061.08	2,569.52	3,191.31	2,569.52	11,676.09
II	Expenses						
	Cost of Material Consumed	2,564.17	2,259.09	2,248.65	2,564.17	2,248.65	9,715.42
	Change In Inventories	(4.18)	10.87	(1.64)	(4.18)	(1.64)	(12.65)
	Employee benefit expenses	99.21	59.01	57.28	99.21	57.28	275.73
	Finance costs	8.46	5.68	15.02	8.46	15.02	33.43
	Depreciation and amortization expenses	24.83	38.10	22.32	24.83	22.32	109.35
	Payment to NSE						
	Other expenses	396.10	497.14	165.29	396.10	165.29	1,121.88
	Total expenses	3,088.59	2,869.89	2,506.92	3,088.59	2,506.92	11,243.16
III	Profit/(Loss) before exceptional items and tax	102.72	191.19	62.60	102.72	62.60	432.93
IV	Exceptional items						
V	Profit/(Loss) before tax	102.72	191.19	62.60	102.72	62.60	432.93
VI	Tax expenses						
	a) Current tax	22.50	49.24	15.20	22.50	15.20	102.42
	b) Deferred tax	-2.08	12.44	(0.58)	(2.08)	(0.58)	6.70
	b) Mat Credit						
VII	Net Profit/(Loss) for the period/year	78.14	154.39	46.82	78.14	46.82	337.21
VIII	Other comprehensive income (net of tax)						
	loss:		(82.38)		-		(26.10)
	Total other comprehensive income		(82.38)				(26.10)
IX	Total comprehensive income for the period/year (VII+VIII)	78.14	72.01	46.82	78.14	46.82	311.10




X	Paid-up equity share capital (face value of the share shall be indicated)	3,444.87	3,444.87	3,444.87	3,444.87	3,444.87	3,444.87
XI	Other equity (excluding revaluation reserve)	5,441.16	5,363.02	5,104.74	5,441.16	5,104.74	5,363.02
XII	EPS in Rs. (Face Value of Rs.10/- each)*						
	-Basic	0.02	0.09	0.03	0.02	0.23	0.20
	-Diluted	0.02	0.09	0.03	0.02	0.23	0.20
Notes:							
1. The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 11.08.2025 after being reviewed by the Audit Committee.							
2. The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company.							
3. Due to re-grouping of schedules, and as per applicability of IND-AS, there has been a difference in the figures as reported earlier.							
For Ajooni Biotech Limited Jasjot Singh Managing Director DIN: 01937631 Place : Mohali Date : 14/08/2025							



Statement of Assets and Liabilities
For the Quarter ended on 30th June 2025

		in Rs. (Lakhs)	
	PARTICULARS	30TH JUNE 2025	31ST MARCH 2025
I. ASSETS			
(1) Non - Current Assets			
-	a) Property, Plant and Equipment	1,469.76	1,093.31
-	b) Capital Work In Progress	224.11	29.29
-	c) Investment Property		-
-	d) Goodwill		-
-	e) Other Intangible Assets	44.94	47.93
-	f) Intangible Assets Under Development		-
-	g) Biological Assets other than Bearer Plants		-
-	h) Financial Assets		
	(1) Investments	388.16	349.36
	(2) Trade Receivables		-
	(3) Loans		-
	(4) Other Financial Assets	0.00	1,506.79
	i) Deffered Tax Asset (net)	40.00	37.92
	j) Other Non Current Asset	201.52	240.11
(2) Current Assets			
	a) Inventories	2,604.07	2,398.69
	b) Financial Assets		
	(1) Investments		
	(2) Trade Receivables	1,876.06	1,621.64
	(3) Cash & Cash Equivalent	1,574.89	683.02
	(4) Bank Balances other than (iii) above		
	(5) Loans	1,333.90	1,330.65
	(6) Other Financial Asset		27.37
	c) Current Tax Assets (net)		-
	d) Other Current Asset	235.11	139.03
	TOTAL	9,992.52	9,505.11



II EQUITY AND LIABILITIES**(1) Equity**

a) Equity Share Capital	3,444.87	3,444.87
b) Other Equity	5,441.16	5,363.02

(2) Non-Current Liabilities

a) Financial Liabilities		
(1) Borrowings	536.94	193.97
(2) Trade Payables		
(3) Other Financial Liabilities		
b) Employee Benefit Obligations	22.06	21.13
c) Deferred Tax Liability (net)		-
d) Other Non Current Liability		-

(3) Current Liabilities

a) Financial Liabilities		
(1) Borrowings	0.00	0.00
(2) Trade Payables	391.68	349.52
(3) Other Financial Liabilities		
b) Employee Benefit Obligations	1.44	0.93
c) Other Current Liabilities	131.87	29.25
d) Current tax liabilities (Net)	22.50	102.42

TOTAL**9,992.52****9,505.11****Place : Mohali****Date : 14.08.2025****For Ajooni Biotech Limited****Jasjot Singh
Managing
Director
DIN: 01937631**



NARINDER KUMAR AND COMPANY
CHARTERED ACCOUNTANTS

SCO 65-B (1st Floor) City Heart,
Kharar Chandigarh Road,
Kharar, SAS Nagar Mohali-140301
Mobile : 98154 50065
Email : nkgargca@yahoo.co.in

Limited Review Report

Ref. No.

Dated

Review Report to Board of Directors of M/s Ajooni Biotech Limited.

We have reviewed the accompanying statement of unaudited financial results of M/s Ajooni Biotech Limited having Regd. office at D-118, Industrial Area, Phase-VII, Mohali Punjab-160055. for the period ended 30th June 2025.(the Statement) attached herewith , being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations 2015 (as amended) , Including relevant circulars issued by the Securities and Exchange Board of India (SEBI) from time to Time.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For NARINDER KUMAR AND COMPANY

Chartered Accountants



NARINDER KUMAR GARG)

PARTNER

M.NO-080287

Date:-14.08.2025

UDIN:- 25080287BMLIUF5744